ING Group’s iShares Biotechnology ETF IBB Stock Holding History

ING Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,000	Closed	-$549K	–	807
2018 Q2	$549K	Buy	+5,000	New	+$535K	0.01%	434
2017 Q3	–	Sell	-11,340	Closed	-$1.17M	–	855
2017 Q2	$1.17M	Sell	11,340 -15,708	-58%	-$1.55M	0.02%	294
2017 Q1	$2.64M	Hold	27,048	–	–	0.05%	212
2016 Q4	$2.41M	Buy	27,048 +4,800	+22%	+$437K	0.05%	202
2016 Q3	$2.12M	Sell	22,248 -1,200	-5%	-$114K	0.03%	212
2016 Q2	$2.01M	Buy	23,448 +17,694	+308%	+$1.59M	0.03%	195
2016 Q1	$500K	Sell	5,754 -8,994	-61%	-$804K	0.01%	377
2015 Q4	$1.67M	Sell	14,748 -21,300	-59%	-$2.31M	0.01%	441
2015 Q3	$3.63M	Hold	36,048	–	–	0.03%	319
2015 Q2	$4.44M	Sell	36,048 -6,000	-14%	-$718K	0.02%	373
2015 Q1	$4.81M	Hold	42,048	–	–	0.02%	412
2014 Q4	$4.25M	Buy	42,048 +27,048	+180%	+$2.63M	0.02%	405
2014 Q3	$1.37M	Hold	15,000	–	–	0.01%	500
2014 Q2	$1.28M	Sell	15,000 -31,533	-68%	-$2.48M	0.01%	511
2014 Q1	$3.67M	Buy	46,533 +3,678	+9%	+$306K	0.02%	410
2013 Q4	$3.24M	Buy	42,855 +20,853	+95%	+$1.48M	0.02%	414
2013 Q3	$1.54M	Buy	22,002 +4,002	+22%	+$262K	0.01%	520
2013 Q2	$1.04M	Buy	+18,000	New	+$1.04M	0.01%	544

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ING Group's IBB Position: Q3 2018 in Review

ING Group sold out of iShares Biotechnology ETF (IBB) in Q3 2018, closing a stake of 5,000 shares — an estimated $549K sold.

ING Group first reported a position in IBB in Q2 2013 and held it in 18 quarters. The position peaked at $4.81M in Q1 2015. 630 funds tracked by Wall St. Rank hold IBB as of Q3 2018.

ING Group reported no remaining iShares Biotechnology ETF position as of Q3 2018 after selling out during the quarter.
ING Group sold 5,000 iShares Biotechnology ETF shares in Q3 2018, an estimated $549K.
ING Group first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 18 quarters.
ING Group's iShares Biotechnology ETF position peaked at $4.81M in Q1 2015.
630 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2018.

Based on ING Group's 13F filing for Q3 2018, filed 6 Nov 2018.